Clinical trial · Observational
Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin
Pharmacogenomic Study to Predict Toxicity and Response in Colorectal Cancer Patients Treated With Oxaliplatin-based Chemotherapy
NCT00977717CI-TRIAL-00003376completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In order to explore genetic factors that may determine the neurotoxicity of oxaliplatin-based chemotherapy, germinal gene polymorphisms will be analyzed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Curatively Resected Stage III Colon Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- FOLFOX
- description
- Stage III colorectal cancer patients who are treated with adjuvant FOLFOX chemotherapy
Primary outcomes (1)
- measure
- neuropathy
- timeFrame
- six months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * aged 18 or older * curatively resected colon adenocarcinoma * pathologically staged III * adequate performance status * adequate major organ functions * to be treated with adjuvant FOLFOX chemotherapy * written informed consent Exclusion Criteria: * those who disagree the study
References
Publications (1)
- DERIVEDBaek KK, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Cho YB, Yun SH, Kim HC, Lee WY, Chun HK. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat. 2010 Dec;42(4):185-90. doi: 10.4143/crt.2010.42.4.185. Epub 2010 Dec 31. PMID 21253319